Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs

This novel editing approach might unlock new strategies for the treatment of metabolic and neurological diseasesNon-viral circular ssDNA delivery associated to TALEN® gene editing allows high...

Related Keywords

United States ,Raleigh ,North Carolina ,France ,Paris ,France General ,New York ,American ,Arthur Stril ,Pascalyne Wilson ,Ashleyr Robinson ,Patricia Sosa Navarro ,Alex Boyne ,Julien Valton ,American Society Of Gene ,Cellectis The Company Euronext Growth ,Securities Exchange Commission ,Nasdaq ,Euronext Growth ,American Society ,Cell Therapy ,Vice President ,Gene Therapy ,Intron Editing ,Lineage Specific Expression ,Vice President Gene Therapy ,Gene Targeting ,Gene Correction New Technologies ,Exhibit Hall ,Abstract Number ,Non Viral Single Strand ,Gene Correction ,Gene Insertion Improves Editing Outcomes ,Gene Editing Platform Manager ,Nonviral Therapeutic Gene Delivery ,Molecular Conjugates ,Nasdaq Global Market ,Private Securities Litigation Reform Act ,Annual Report ,Sosa Navarro ,Chief Business Officer ,Lifesci Advisors ,Markets ,